Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

SOPHiA GENETICS SA

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON , NOV. 11, 2025 /PRNEWSWIRE/ -- COMPLETE GENOMICS, A LEADING INNOVATOR IN GENOMIC SEQUENCING, TODAY ANNOUNCED A COLLABORATION WITH SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TO LAUNCH AND CO-MARKET MSK-ACCESS AND MSK-IMPACT POWERED WITH SOPHIA DDM ON COMPLETE GENOMICS' DNBSEQ-T1+ SEQUENCING PLATFORM. THE COMPANIES AIM TO BROADEN ACCESS TO PRECISION ONCOLOGY TESTING BY OFFERING THE BEST-IN-CLASS LIQUID BIOPSY AND SOLID TUMOR APPLICATIONS TO CUSTOMERS GLOBALLY.

SOPHIA GENETICS AND COMPLETE GENOMICS INTEGRATE SEQUENCING AND AI ANALYTICS TO ACCELERATE ADOPTION OF PRECISION MEDICINE

BOSTON AND SAN DIEGO , NOV. 11, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, AND ELEMENT BIOSCIENCES, INC.,A BIOLOGY COMPANY TRANSFORMING THE PACE AND ACCESSIBILITY OF SCIENTIFIC DISCOVERY, TODAY ANNOUNCED AT THE ASSOCIATION FOR MOLECULAR PATHOLOGY (AMP) ANNUAL MEETING A PARTNERSHIP THAT UNITES SEQUENCING AND AI ANALYTICS TO STREAMLINE GENOMIC WORKFLOWS AND ACCELERATE THE RESEARCH SUPPORTING PRECISION MEDICINE. THIS COLLABORATION INTEGRATES SOPHIA GENETICS' AI-POWERED ANALYTICS PLATFORM, SOPHIA DDM, WITH ELEMENT'S AVITI24 5D MULTIOMIC ANDAVITI SEQUENCING SYSTEMS TO DELIVER A SEAMLESS, END-TO-END WORKFLOW FOR NEXT-GENERATION SEQUENCING (NGS).

SOPHIA GENETICS AND ELEMENT BIOSCIENCES UNITE SEQUENCING POWER AND AI ANALYTICS TO ACCELERATE GLOBAL RESEARCH IN PRECISION MEDICINE

BOSTONAND ROLLE, SWITZERLAND , NOV. 4, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. THIRD QUARTER 2025 FINANCIAL RESULTS REVENUE WAS $19.5 MILLION, UP 23% YEAR-OVER-YEAR GROSS MARGIN WAS 66.3% ON A REPORTED BASIS AND 73.1% ON AN ADJUSTED BASIS, COMPARED TO 67.2% REPORTED AND 73.1% ADJUSTED IN THE PRIOR YEAR PERIOD NET IFRS LOSS WAS $20.0 MILLION, UP 9% YEAR-OVER-YEAR; ADJUSTED EBITDA LOSS WAS $10.2 MILLION, UP 8% YEAR-OVER-YEAR; EXCLUDING THE IMPACT OF ELEVATED SWISS SOCIAL CHARGES ON EQUITY-BASED COMPENSATION FOLLOWING SHARE PRICE APPRECIATION, ADJUSTED EBITDA LOSS WOULD HAVE BEEN $8.8 MILLION, REPRESENTING A 13% YEAR-OVER-YEAR IMPROVEMENT 2025 FINANCIAL OUTLOOK FULL YEAR REVENUE IS NOW EXPECTED TO BE IN THE RANGE OF $75 TO $77 MILLION, REPRESENTING YEAR-OVER-YEAR GROWTH OF 15% TO 18%.

SOPHiA GENETICS SA

SOPH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SOPHiA GENETICS SA

SOPH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SOPH